Feasibility of Using Population Pharmacokinetics‐Based Virtual Control Groups in Organ Impairment Studies
Open Access
- 12 February 2024
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (6) , 713-718
Abstract
This work aimed to assess the feasibility of using population pharmacokinetics (popPK) to generate virtual healthy control groups in organ impairment studies. Data from 11 organ impairment studies containing 18 organ impairment arms and 13 healthy control groups across 7 drugs were analyzed. Area under the concentration‐time curve (AUC) and maximum concentration (Cmax) were calculated from popPK‐simulated individual concentration‐time profiles for participants in the healthy control groups, accounting for the participant's specific covariate(s) (N = 1000 replicates). The AUC and Cmax geometric mean ratios (GMRs; simulated healthy control/observed healthy control and observed organ impairment/simulated healthy control) were calculated. The simulated healthy control group geometric mean exposures were within 30% of the observed geometric mean exposures in 8 of the 11 studies (73%). The number of organ impairment arms for which the observed GMR (observed organ impairment/observed healthy control) and median of simulation‐based GMRs (observed organ impairment/simulated healthy control) for AUC and Cmax being within the same fold change were 12 (67%) and 13 (72%) arms, respectively. The number of organ impairment arms for which the median of simulation‐based AUC and Cmax GMRs were within the 90% confidence interval of the observed GMRs were 14 (72%) and 15 (83%), respectively. Poor concordance was observed for 1 drug (3 arms), where healthy participants' data were not incorporated in the popPK model. This work supports using popPK‐based virtual control groups in organ impairment studies. Subsequent work should aim to establish best practices for constructing popPK‐based virtual control groups.Keywords
This publication has 12 references indexed in Scilit:
- Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib PharmacokineticsThe AAPS Journal, 2023
- Design and conduct considerations for studies in patients with hepatic impairmentClinical and Translational Science, 2022
- The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug TrialsThe Journal of Clinical Pharmacology, 2022
- Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic PredictionsThe Journal of Clinical Pharmacology, 2021
- Design and conduct considerations for studies in patients with impaired renal functionClinical and Translational Science, 2021
- Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry PerspectiveClinical Pharmacology & Therapeutics, 2020
- Model‐Informed Drug Development: Current US Regulatory Practice and Future ConsiderationsClinical Pharmacology & Therapeutics, 2019
- Serial Participation and the Ethics of Phase 1 Healthy Volunteer ResearchThe Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine, 2018
- An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokineticsThe Journal of Clinical Pharmacology, 2015
- Pharmacokinetics of Ertapenem in Patients With Varying Degrees of Renal Insufficiency and in Patients on HemodialysisThe Journal of Clinical Pharmacology, 2006